The microbiome and sustainable healthcare

Healthcare (Switzerland)

Volumn 3, Issue 1, 2015, Pages 100-129

  Dietert, Rodney R ^a   Dietert, Janice M ^b  

^a Cornell University ^*  (United States)

^b Performance Plus Consulting   (United States)

Author keywords

Antibiotic resistance; Archaea; Bacteria; Economic burden; Gut microbiota; Immune maturation; Microbiome reconstitution; Non communicable diseases; Personalized medicine; Pregnancy

Indexed keywords

EID: 84969424786     PISSN: None     EISSN: 22279032     Source Type: Journal    
DOI: 10.3390/healthcare3010100     Document Type: Review

References (204)

1. Bloom, D.E.; Cafiero, E.T.; Jané-Llopis, E.; Abrahams-Gessel, S.; Bloom, L.R.; Fathima, S.; Feigel, A.B.; Gaziano, T.; Mowafi, M.; Pandya, A.; et al. The Global Economic Burden of Noncommunicable Diseases; World Economic Forum: Geneva, Switzerland, 2011.
2. Cantón, R.; Horcajada, J.P.; Oliver, A.; Garbajosa, P.R.; Vila, J. Inappropriate use of antibiotics in hospitals: The complex relationship between antibiotic use and antimicrobial resistance. Enferm. Infecc. Microbiol. Clin. 2013, 4, 3–11.
3. Hughes, D. Selection and evolution of resistance to antimicrobial drugs. IUBMB Life 2014, 66, 521–529.
4. Goodacre, R. Metabolomics of a superorganism. J. Nutr. 2007, 137, 259S–266S.
5. Rogers, G.B. The human microbiome: Opportunities and challenges for clinical care. Intern. Med. J. 2014, doi:10.1111/imj.12650.
6. Mayer, E.A.; Knight, R.; Mazmanian, S.K.; Cryan, J.F.; Tillisch, K. Gut microbes and the brain: Paradigm shift in neuroscience. J. Neurosci. 2014, 34, 15490–15496.
7. Tang, W.H.; Hazen, S.L. The contributory role of gut microbiota in cardiovascular disease. J. Clin. Investig. 2014, 124, 4204–4211.
8. Sudo, N. Microbiome, HPA axis and production of endocrine hormones in the gut. Adv. Exp. Med. Biol. 2014, 817, 177–194.
9. Biesbroek, G.; Tsivtsivadze, E.; Sanders, E.A.; Montijn, R.; Veenhoven, R.H.; Keijser, B.J.; Bogaer, T.D. Early respiratory microbiota composition determines bacterial succession patterns and respiratory health in children. Am. J. Respir. Crit. Care Med. 2014, 190, 1283–1292.
10. Spasova, D.S.; Surh, C.D. Blowing on embers: Commensal microbiota and our immune system. Front. Immunol. 2014, 5, 318.
11. Ohlsson, C.; Engdahl, C.; Fåk, F.; Andersson, A.; Windahl, S.H.; Farman, H.H.; Movérare-Skrtic, S.; Islander, U.; Sjögren, K. Probiotics protect mice from ovariectomy-induced cortical bone loss. PLoS One 2014, 9, e92368.
12. Zhu, B.; Wang, X.; Li, L. Human gut microbiome: The second genome of human body. Protein Cell 2010, 1, 718–725.
13. Gilbert, S.F. A holobiont birth narrative: The epigenetic transmission of the human microbiome. Front. Genet. 2014, 5, 282.
14. Parfrey, L.W.; Walters, W.A.; Lauber, C.L.; Clemente, J.C.; Berg-Lyons, D.; Teiling, C.; Kodira, C.; Mohiuddin, M.; Brunelle, J.; Driscoll, M.; et al. Communities of microbial eukaryotes in the mammalian gut within the context of environmental eukaryotic diversity. Front. Microbiol. 2014, 5, 298.
15. Gaci, N.; Borrel, G.; Tottey, W.; O’Toole, P.W.; Brugère, J.F. Archaea and the human gut: New beginning of an old story. World J. Gastroenterol. 2014, 20, 16062–16078.
16. Canganella, F.; Wiegel, J. Anaerobic thermophiles. Life 2014, 4, 77–104.
17. Gilbert, S.F.; Sapp, J.; Tauber, A.I. A symbiotic view of life: We have never been individuals. Q. Rev. Biol. 2012, 87, 325–341.
18. Dietert, R.R.; Dietert, J.M. The completed self: An immunological view of the human-microbiome superorganism and risk of chronic diseases. Entropy 2012, 14, 2036–2065.
19. Dietert, R.R. The microbiome in early life: Self-completion and microbiota protection as health priorities. Birth Defects Res. B Dev. Reprod. Toxicol. 2014, 101, 333–340.
20. Salvucci, E. Microbiome, holobiont and the net of life. Crit. Rev. Microbiol. 2014, 28, 1–10.
21. Lahti, L.; Salojärvi, J.; Salonen, A.; Scheffer, M.; de Vos, W.M. Tipping elements in the human intestinal ecosystem. Nat. Commun. 2014, 5, 4344.
22. Campbell, N.R.; Niebylski, M.L.; World Hypertension League Executive. Prevention and control of hypertension: Developing a global agenda. Curr. Opin. Cardiol. 2014, 29, 324–330.
23. Murray, C.J.; Vos, T.; Lozano, R.; Naghavi, M.; Flaxman, A.D.; Michaud, C.; Ezzati, M.; Shibuya, K.; Salomon, J.A.; Abdalla, S.; et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2197–2223.
24. Peck, R.; Mghamba, J.; Vanobberghen, F.; Kavishe, B.; Rugarabamu, V.; Smeeth, L.; Haye, S.R.; Grosskurth, H.; Kapig, A.S. Preparedness of Tanzanian health facilities for outpatient primary care of hypertension and diabetes: A cross-sectional survey. Lancet Glob. Health 2014, 2, e285–e292.
25. Ali, M.K.; Rabadán-Diehl, C.; Flanigan, J.; Blanchard, C.; Narayan, K.M.; Engelgau, M. Systems and capacity to address noncommunicable diseases in low-and middle-income countries. Sci. Transl. Med. 2013, 5, 181cm4.
26. Cohen, D.L.; Townsend, R.R.; Angell, S.Y; DiPette, D.J. The world health organization recognizes noncommunicable diseases and raised blood pressure as global health priority for 2025. J. Clin. Hypertens. 2014, 16, 624.
27. World Health Organization, NCD Global Monitoring Framework. Ensuring Progress on Noncommunicable Diseases in Countries. Available online: http://www.who.int/nmh/global_ monitoring_framework/en/(accessed on 16 November 2014).
28. Sleator, R.D. The human superorganism of microbes and men. Med. Hypotheses 2010, 74, 214–215.
29. Garmendia, M.L.; Corvalan, C.; Uauy, R. Assessing the public health impact of developmental origins of health and disease (DOHaD) nutrition interventions. Ann. Nutr. Metab. 2014, 64, 226–230.
30. Prescott, S.L. Disease prevention in the age of convergence—The need for a wider, long ranging and collaborative vision. Allergol. Int. 2014, 63, 11–20.
31. Munyaka, P.M.; Khafipour, E.; Ghi, A.J.E. External influence of early childhood establishment of gut microbiota and subsequent health implications. Front. Pediatr. 2014, 2, 109.
32. Collado, M.C.; Rautava, S.; Isolauri, E.; Salminen, S. Gut microbiota: Source of novel tools to reduce the risk of human disease? Pediatr. Res. 2014, doi:10.1038/pr.2014.173.
33. Li, J.; Jia, H.; Cai, X.; Zhong, H.; Feng, Q.; Sunagawa, S.; Arumugam, M.; Kultima, J.R.; Prifti, E.; Nielsen, T.; et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 2014, 32, 834–841.
34. Verbeke, K.A.; Boesmans, L.; Boets, E. Modulating the microbiota in inflammatory bowel diseases: Prebiotics, probiotics or faecal transplantation? Proc. Nutr. Soc. 2014, 73, 490–497.
35. Huang, Y.J.; Boushey, H.A. The microbiome and asthma. Ann. Am. Thorac. Soc. 2014, 1, S48–S51.
36. Kong, H.H.; Oh, J.; Deming, C.; Conlan, S.; Grice, E.A.; Beatson, M.A.; Nomicos, E.; Polley, E.C.; Komarow, H.D.; NISC Comparative Sequence Program; et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012, 22, 850–859.
37. MacFabe, D. Autism: Metabolism, mitochondria, and the microbiome. Glob. Adv. Health Med. 2013, 2, 52–66.
38. Consolandi, C.; Turroni, S.; Emmi, G.; Severgnini, M.; Fiori, J.; Peano, C.; Biagi, E.; Grassi, A.; Rampelli, S.; Silvestri, E.; et al. Behçet’s syndrome patients exhibit specific microbiome signature. Autoimmun. Rev. 2014, doi:10.1016/j.autrev.2014.11.009.
39. Xuan, C.; Shamonki, J.M.; Chung, A.; Dinome, M.L.; Chung, M.; Sieling, P.A.; Lee, D.J. Microbial dysbiosis is associated with human breast cancer. PLoS One 2014, 9, e83744.
40. Serino, M.; Blasco-Baque, V.; Nicolas, S.; Burcelin, R. Far from the eyes, close to the heart: Dysbiosis of gut microbiota and cardiovascular consequences. Curr. Cardiol. Rep. 2014, 16, 540.
41. Koeth, R.A.; Wang, Z.; Levison, B.S.; Buffa, J.A.; Org, E.; Sheehy, B.T.; Britt, E.B.; Fu, X.; Wu, Y.; Li, L.; et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013, 19, 576–585.
42. De Sousa Moraes, L.F.; Grzeskowiak, L.M.; de Sales Teixeira, T.F.; Gouveia Peluzio Mdo, C. Intestinal microbiota and probiotics in celiac disease. Clin. Microbiol. Rev. 2014, 27, 482–489.
43. Sabatino, A.; Regolisti, G.; Brusasco, I.; Cabassi, A.; Morabito, S.; Fiaccadori, E. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol. Dial. Transplant. 2014, doi:10.1093/ndt/gfu287.
44. Huang, Y.J.; Sethi, S.; Murphy, T.; Nariya, S.; Boushey, H.A.; Lynch, S.V. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J. Clin. Microbiol. 2014, 52, 2813–2823.
45. Kirst, M.E.; Li, E.C.; Alfant, B.; Chi, Y.Y.; Walker, C.; Magnusson, I.; Wang, G.P. Dysbiosis and alterations in predicted functions of subgingival microbiome in chronic periodontitis. Appl. Environ. Microbiol. 2015, 81, 783–793.
46. Akin, H.; Tözün, N. Diet, microbiota, and colorectal cancer. J. Clin. Gastroenterol. 2014, 48, S67–S69.
47. Louis, P.; Hold, G.L.; Flint, H.J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 2014, 12, 661–672.
48. Sartor, R.B. The intestinal microbiota in inflammatory bowel diseases. Nestle Nutr. Inst. Workshop Ser. 2014, 79, 29–39.
49. De Cruz, P.; Kang, S.; Wagner, J.; Buckley, M.; Sim, W.H.; Prideaux, L.; Lockett, T.; McSweene, Y.C.; Morrison, M.; Kirkwood, C.D.; et al. Specific mucosa-associated microbiota in Crohn’s disease at the time of resection are associated with early disease recurrence: A pilot study. J. Gastroenterol. Hepatol. 2014, doi:10.1111/jgh.12694.
50. Yu, G.; Gail, M.H.; Shi, J.; Klepac-Ceraj, V.; Paster, B.J.; Dye, B.A.; Wang, G.Q.; Wei, W.Q.; Fanm J.H.; Qiao, Y.L.; et al. Association between upper digestive tract microbiota and cancer-predisposing states in the esophagus and stomach. Cancer Epidemiol. Biomark. Prev. 2014, 23, 735–741.
51. Cao, S.; Feehley, T.J.; Nagler, C.R. The role of commensal bacteria in the regulation of sensitization to food allergens. FEBS Lett. 2014, 588, 4258–4266.
52. Wang, L.L.; Yu, X.J.; Zhan, S.H.; Jia, S.J.; Tian, Z.B.; Dong, Q.J. Participation of microbiota in the development of gastric cancer. World J. Gastroenterol. 2014, 20, 4948–4952.
53. Pluznick, J.L.; Protzko, R.J.; Gevorgyan, H.; Peterlin, Z.; Sipos, A.; Han, J.; Brunet, I.; Wan, L.X.; Rey, F.; Wang, T.; et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc. Natl. Acad. Sci. USA 2013, 110, 4410–4415.
54. Gong, H.L.; Shi, Y.; Zhou, L.; Wu, C.P.; Cao, P.Y.; Tao, L.; Xu, C.; Hou, D.S.; Wang, Y.Z. The composition of microbiome in larynx and the throat biodiversity between laryngeal squamous cell carcinoma patients and control population. PLoS One 2013, 8, e66476.
55. Gómez-Hurtado, I.; Such, J.; Sanz, Y.; Francés, R. Gut microbiota-related complications in cirrhosis. World J. Gastroenterol. 2014, 20, 15624–15631.
56. Hosgood, H.D., 3rd; Sapkota, A.R.; Rothman, N.; Rohan, T.; Hu, W.; Xu, J.; Vermeulen, R.; He, X.; White, J.R.; Wu, G.; et al. The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. Environ. Mol. Mutagen. 2014, 55, 643–651.
57. Bhargava, P.; Mowry, E.M. Gut microbiome and multiple sclerosis. Curr. Neurol. Neurosci. Rep. 2014, 14, 492.
58. Zhu, L.; Baker, S.S.; Gill, C.; Liu, W.; Alkhouri, R.; Baker, R.D.; Gill, S.R. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology 2013, 57, 601–609.
59. Bradlow, H.L. Obesity and the gut microbiome: Pathophysiological aspects. Horm. Mol. Biol. Clin. Investig. 2014, 17, 53–61.
60. Farrell, J.J.; Zhang, L.; Zhou, H.; Chia, D.; Elashoff, D.; Akin, D.; Paster, B.J.; Joshipura, K.; Wong, D.T. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 2012, 61, 582–588.
61. Scheperjans, F.; Aho, V.; Pereira, P.A.; Koskinen, K.; Paulin, L.; Pekkonen, E.; Haapaniemi, E.; Kaakkola, S.; Eerola-Rautio, J.; Pohja, M.; et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov. Disord. 2014, doi:10.1002/mds.26069.
62. Sugiyama, Y.; Masumori, N.; Fukuta, F.; Yoneta, A.; Hida, T.; Yamashita, T.; Minatoya, M.; Nagata, Y.; Mori, M.; Tsuji, H.; et al. Influence of isoflavone intake and equol-producing intestinal flora on prostate cancer risk. Asian Pac. J. Cancer Prev. 2013, 14, 1–4.
63. Alekseyenko, A.V.; Perez-Perez, G.I.; de Souza, A.; Strober, B.; Gao, Z.; Bihan, M.; Li, K.; Methé, B.A.; Blaser, M.J. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome 2013, 1, 31.
64. Taneja, V. Arthritis susceptibility and the gut microbiome. FEBS Lett. 2014, 588, 4244–4249.
65. Hevia, A.; Milani, C.; López, P.; Cuervo, A.; Arboleya, S.; Duranti, S.; Turroni, F.; González, S.; Suárez, A.; Gueimonde. M.; et al. Intestinal dysbiosis associated with systemic lupus erythematosus. MBio 2014, 5, e01548–e01614.
66. De Goffau, M.C.; Fuentes, S.; van den Bogert, B.; Honkanen, H.; de Vos, W.M.; Welling, G.W.; Hyöty, H.; Harmsen, H.J. Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. Diabetologia 2014, 57, 1569–1577.
67. Moreno-Indias, I.; Cardona, F.; Tinahones, F.J.; Queipo-Ortuño, M.I. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front. Microbiol. 2014, 5, 190.
68. Machiels, K.; Joossens, M.; Sabin, J.; de Preter, V.; Arijs, I.; Eeckhaut, V.; Ballet, V.; Claes, K.; van Immerseel, F.; Verbeke, K.; et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014, 63, 1275–1283.
69. Brown, K. The history of penicillin from discovery to the drive to production. Pharm. Hist. (Lond.) 2004, 34, 37–43.
70. Kardos, N.; Demain, A.L. Penicillin: The medicine with the greatest impact on therapeutic outcomes. Appl. Microbiol. Biotechnol. 2011, 92, 677–687.
71. Shallcross, L.J.; Davies, D.S. Antibiotic overuse: A key driver of antimicrobial resistance. Br. J. Gen. Pract. 2014, 64, 604–605.
72. Laxminarayan, R.; Duse, A.; Wattal, C.; Zaidi, A.K.; Wertheim, H.F.; Sumpradit, N.; Vlieghe, E.; Hara, G.L.; Gould, I.M.; Goossens, H.; et al. Antibiotic resistance-the need for global solutions. Lancet Infect. Dis. 2013, 13, 1057–1098.
73. Tomson, G.; Vlad, I. The need to look at antibiotic resistance from a health systems perspective. Upsala J. Med. Sci. 2014, 119, 117–124.
74. Lee, T.C.; Frenette, C.; Jayaraman, D.; Green, L.; Pilote, L. Antibiotic self-stewardship: Trainee-led structured antibiotic time-outs to improve antimicrobial use. Ann. Intern. Med. 2014, 161, S53–S58.
75. Nitsch-Osuch, A.; Kurpas, D.; Kuchar, E.; Zycińska, K.; Zielonka, T.; Wardyn, K. Antibiotic consumption pattern in the neonatal special care unit before and after implementation of the hospital's antibiotic policy. Adv. Exp. Med. Biol. 2015, 835, 45–51.
76. Edelsberg, J.; Weycker, D.; Barron, R.; Li, X.; Wu, H.; Oster, G.; Badre, S.; Langeberg, W.J.; Weber, D.J. Prevalence of antibiotic resistance in US hospitals. Diagn. Microbiol. Infect. Dis. 2014, 78, 255–262.
77. Llor, C.; Bjerrum, L. Antimicrobial resistance: Risk associated with antibiotic overuse and initiatives to reduce the problem. Ther. Adv. Drug Saf. 2014, 5, 229–241.
78. Venekamp, R.P.; Sanders, S.; Glasziou, P.P.; del Mar, C.B.; Rovers, M.M. Antibiotics for acute otitis media in children. Cochrane Database Syst. Rev. 2013, 1, CD000219.
79. Milligan, S.; McCrery, S. Should children with acute otitis media routinely be treated with antibiotics? No: Most children older than two years do not require antibiotics. Am. Fam. Physician. 2013, 88, online.
80. Mehndiratta, P.L.; Bhalla, P. Use of antibiotics in animal agriculture & emergence of methicillin-resistant Staphylococcus aureus (MRSA) clones: Need to assess the impact on public health. Indian J. Med. Res. 2014, 140, 339–344.
81. Wayne, A.; McCarthy, R.; Lindenmayer, J. Therapeutic antibiotic use patterns in dogs: Observations from a veterinary teaching hospital. J. Small Anim. Pract. 2011, 52, 310–318.
82. Baquero, F.; Nombela, C. The microbiome as a human organ. Clin. Microbiol. Infect. 2012, 18, 2–4.
83. Guinane, C.M.; Cotter, P.D. Role of the gut microbiota in health and chronic gastrointestinal disease: Understanding a hidden metabolic organ. Ther. Adv. Gastroenterol. 2013, 6, 295–308.
84. Vitetta, L.; Manuel, R.; Zhou, J.Y.; Linnane, A.W.; Hall, S.; Coulson, S. The overarching influence of the gut microbiome on end-organ function: The role of live probiotic cultures. Pharmaceuticals 2014, 7, 954–989.
85. Cox, L.M.; Blaser, M.J. Antibiotics in early life and obesity. Nat. Rev. Endocrinol. 2014, doi:10.1038/nrendo.2014.210.
86. Karczewski, J.; Poniedziałek. B.; Adamski, Z.; Rzymski, P. The effects of the microbiota on the host immune system. Autoimmunity 2014, 47, 494–504.
87. Shivashankar, R.; Khanna, S.; Kammer, P.P.; Scott Harmsen, W.; Zinsmeister, A.R.; Baddour; L.M.; Pardi, D.S. Clinical predictors of recurrent Clostridium difficile infection in out-patients. Aliment. Pharmacol. Ther. 2014, 40, 518–522.
88. Bibbò, S.; Lopetuso, L.R.; Ianiro, G.; di Rienzo, T.; Gasbarrini, A.; Cammarota, G. Role of microbiota and innate immunity in recurrent Clostridium difficile infection. J. Immunol. Res. 2014, 2014, 462740.
89. De Tejada, B.M. Antibiotic use and misuse during pregnancy and delivery: Benefits and risks. Int. J. Environ. Res. Public Health 2014, 11, 7993–8009.
90. Buffie, C.G.; Bucci, V.; Stein, R.R.; McKenney, P.T.; Ling, L.; Gobourne, A.; No, D.; Liu, H.; Kinnebrew, M.; Viale, A.; et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2014, doi:10.1038/nature13828.
91. Youngster, I.; Russell, G.H.; Pindar, C.; Ziv-Baran, T.; Sauk, J.; Hohmann, E.L. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014, 312, 1772–1778.
92. Khoruts, A.; Sadowsky, M.J.; Hamilton, M.J. Development of fecal microbiota transplantation suitable for mainstream medicine. Clin. Gastroenterol. Hepatol. 2014, doi:10.1016/j.cgh.2014.11.014.
93. Ackland, M.L.; Bornhorst, J.; Dedoussis, G.; Dietert, R.R.; Nriagu, J.; Pacyna, J.; Pettifer, J. Metals in the Environment as Risk Factors for Infectious Diseases. In Trace Metals and Infectious Diseases; Strungmann Forum Report; Jerome, O.N., Eric, P.S., Eds.; MIT Press: Cambridge, MA, USA, 2015; Volume 16.
94. Greenblum, S.; Turnbaugh, P.J.; Borenstein, E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc. Natl. Acad. Sci. USA 2012, 109, 594–599.
95. Ridaura, V.K.; Faith, J.J.; Rey, F.E.; Cheng, J.; Duncan, A.E.; Kau, A.L.; Griffin, N.W.; Lombard, V.; Henrissat, B.; Bain, J.R.; et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013, 341, doi:10.1126/science.1241214.
96. Eggesbø, M.; Moen, B.; Peddada, S.; Baird, D.; Rugtveit, J.; Midtvedt, T.; Bushel, P.R.; Sekelja, M.; Rudi. K. Development of gut microbiota in infants not exposed to medical interventions. APMIS 2011, 119, 17–35.
97. Hoskin-Parr, L.; Teyhan, A.; Blocker, A.; Henderson, A.J. Antibiotic exposure in the first two years of life and development of asthma and other allergic diseases by 7.5 years: A dose-dependent relationship. Pediatr. Allergy Immunol. 2013, 24, 762–771.
98. Ooi, J.H.; Li, Y.; Rogers, C.J.; Cantorna, M.T. Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. J. Nutr. 2013, 143, 1679–1686.
99. De Theije, C.G.; Wopereis, H.; Ramadan, M.; van Eijndthoven, T.; Lambert, J.; Knol, J.; Garssen, J.; Kraneveld, A.D.; Oozeer, R. Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav. Immun. 2014, 37, 197–206.
100. Wang, L.; Conlon, M.A.; Christophersen, C.T.; Sorich, M.J.; Angley M.T. Gastrointestinal microbiota and metabolite biomarkers in children with autism spectrum disorders. Biomark Med. 2014, 8, 331–344.
101. Foley, K.A.; MacFabe, D.F.; Kavaliers, M.; Ossenkopp, K.P. Sexually dimorphic effects of prenatal exposure to lipopolysaccharide, and prenatal and postnatal exposure to propionic acid, on acoustic startle response and prepulse inhibition in adolescent rats: Relevance to autism spectrum disorders. Behav. Brain Res. 2014, 278C, 244–256.
102. Frye, R.E.; Melnyk, S.; Macfabe, D.F. Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder. Transl. Psychiatry 2013, 3, e220.
103. Nankova, B.B.; Agarwal, R.; MacFabe, D.F.; La Gamma, E.F. Enteric bacterial metabolites propionic and butyric acid modulate gene expression, including CREB-dependent catecholaminergic neurotransmission, in PC12 cells—Possible relevance to autism spectrum disorders. PLoS One 2014, 9, e103740.
104. An, D.; Oh, S.F.; Olszak, T.; Neves, J.F.; Avci, F.Y.; Erturk-Hasdemir, D.; Lu, X.; Zeissig, S.; Blumberg, R.S.; Kasper, D.L.; et al. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell 2014, 156, 123–133.
105. Biasucci, G.; Rubini, M.; Riboni, S.; Morelli, L.; Bessi, E.; Retetangos, C. Mode of delivery affects the bacterial community in the newborn gut. Early Hum. Dev. 2010, 86, 13–15.
106. Jakobsson, H.E.; Abrahamsson, T.R.; Jenmalm, M.C.; Harris, K.; Quince, C.; Jernberg, C.; Björkstén, B.; Engstrand, L.; Andersson, A.F. Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by caesarean section. Gut 2014, 63, 559–566.
107. Mårild, K.; Stephansson, O.; Montgomery, S.; Murray, J.A.; Ludvigsson, J.F. Pregnancy outcome and risk of celiac disease in offspring: A nationwide case-control study. Gastroenterology 2012, 142, 39–45.
108. Bonifacio, E.; Warncke, K.; Winkler, C.; Wallner, M.; Ziegler, A.G. Cesarean section and interferon-induced helicase gene polymorphisms combine to increase childhood type 1 diabetes risk. Diabetes 2011, 60, 3300–3306.
109. Kahr, N.; Naeser, V.; Stensballe, L.G.; Kyvik, K.O.; Skytthe, A.; Backer, V.; Bønnelykke, K.; Thomsen, S.F. Gene-environment interaction in atopic diseases: A population-based twin study of early-life exposures. Clin. Respir. J. 2014, doi:10.1111/crj.12110.
110. Dutta, S.K.; Girotra, M.; Garg, S.; Dutta, A.; von Rosenvinge, E.C.; Maddox, C.; Song, Y.; Bartlett, J.G.; Vinayek, R.; Fricke, W.F.; et al. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile Infection. Clin. Gastroenterol. Hepatol. 2014, 12, 1572–1576.
111. Fuentes, S.; van Nood, E.; Tims, S.; Heikamp-de Jong, I.; Ter Braak, C.J.; Keller, J.J.; Zoetendalm, E.G.; de Vos, W.M. Reset of a critically disturbed microbial ecosystem: Faecal transplant in recurrent Clostridium difficile infection. ISME J. 2014, doi:10.1038/ismej.2014.13.
112. Austin, M.; Mellow, M.; Tierney, W.M. Fecal Microbiota Transplantation in the Treatment of Clostridium difficile Infections. Am. J. Med. 2014, 109, 1065–1071.
113. Murphy, R.; Stewart, A.W.; Braithwaite, I.; Beasley, R.; Hancox, R.J.; Mitchell, E.A.; The ISAAC Phase Three Study Group. Antibiotic treatment during infancy and increased body mass index in boys: An international cross-sectional study. Int. J. Obes. (Lond.) 2013, doi:10.1038/ijo.2013.218.
114. Mårild, K.; Ye, W.; Lebwohl, B.; Green, P.H.; Blaser, M.J.; Card, T.; Ludvigsson, J.F. Antibiotic exposure and the development of coeliac disease: A nationwide case-control study. BMC Gastroenterol. 2013, 13, 109.
115. Mangin, I.; Suau, A.; Gotteland, M.; Brunser, O.; Pochart, P. Amoxicillin treatment modifies the composition of Bifidobacterium species in infant intestinal microbiota. Anaerobe 2010, 16, 433–438.
116. Bassis, C.M.; Theriot, C.M.; Young, V.B. Alteration of the Murine Gastrointestinal Microbiota by Tigecycline Leads to Increased Susceptibility to Clostridium difficile Infection. Antimicrob. Agents Chemother. 2014, 58, 2767–2774.
117. Wolf, K.J.; Daft, J.G.; Tanner, S.M.; Hartmann, R.; Khafipour, E.; Lorenz, R.G. Consumption of acidic water alters the gut microbiome and decreases the risk of diabetes in NOD mice. J. Histochem. Cytochem. 2014, 62, 237–250.
118. Palmnäs, M.S.; Cowan, T.E.; Bomhof, M.R.; Su, J.; Reimer, R.A.; Vogel, H.J.; Hittel, D.S.; Shearer, J. Low-dose aspartame consumption differentially affects gut microbiota-host metabolic interactions in the diet-induced obese rat. PLoS One 2014, 9, e109841.
119. Zhu, Y.; Jameson, E.; Crosatti, M.; Schäfer, H.; Rajakumar, K.; Bugg, T.D.; Chen, Y. Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc. Natl. Acad. Sci. USA 2014, 111, 4268–4273.
120. Trompette, A.; Gollwitzer, E.S.; Yadava, K.; Sichelstiel, A.K.; Sprenger, N.; Ngom-Bru, C.; Blanchard, C.; Junt, T.; Nicod, L.P.; Harris, N.L.; et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 2014, 20, 159–166.
121. Garg, M.; Rosella, O.; Lubel, J.S.; Gibson, P.R. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm. Bowel Dis. 2013, 19, 2634–2643.
122. Lu, K.; Abo, R.P.; Schlieper, K.A.; Graffam, M.E.; Levine, S.; Wishnok, J.S.; Swenberg, J.A.; Tannenbaum, S.R.; Fox, J.G. Arsenic exposure perturbs the gut microbiome and its metabolic profile in mice: An integrated metagenomics and metabolomics analysis. Environ. Health Perspect. 2014, 122, 284–291.
123. Lu, K.; Mahbub, R.; Cable, P.H.; Ru, H.; Parry, N.M.; Bodnar, W.M.; Wishnok, J.S.; Styblo, M.; Swenberg, J.A.; Fox, J.G.; et al. Gut microbiome phenotypes driven by host genetics affect arsenic metabolism. Chem. Res. Toxicol. 2014, 27, 172–174.
124. Moon, K.A.; Guallar, E.; Umans, J.G.; Devereux, R.B.; Best, L.G.; Francesconi, K.A.; Goessler, W.; Pollak, J.; Silbergeld, E.K.; Howard, B.V.; et al. Association between exposure to low to moderate arsenic levels and incident cardiovascular disease: A prospective cohort study. Ann. Intern. Med. 2013, 159, 649–659.
125. Breton, J.; Massart, S.; Vandamme, P.; de Brandt, E.; Pot, B.; Foligné, B. Ecotoxicology inside the gut: Impact of heavy metals on the mouse microbiome. BMC Pharmacol. Toxicol. 2013, 14, 62.
126. Liu, Y.; Li, Y.; Liu, K.; Shen, J. Exposing to cadmium stress cause profound toxic effect on microbiota of the mice intestinal tract. PLoS One 2014, 9, e85323.
127. Zhang, W.L.; Du, Y.; Zhai, M.M.; Shang, Q. Cadmium exposure and its health effects: A 19-year follow-up study of a polluted area in China. Sci. Total Environ. 2014, 470–471, 224–228.
128. Akesson, A.; Barregard, L.; Bergdahl, I.A.; Nordberg, G.F.; Nordberg, M.; Skerfving, S. Non-renal effects and the risk assessment of environmental cadmium exposure. Environ. Health Perspect. 2014, 122, 431–438.
129. Joly, C.; Gay-Quéheillard, J.; Léké, A.; Chardon, K.; Delanaud, S.; Bach, V.; Khorsi-Cauet, H. Impact of chronic exposure to low doses of chlorpyrifos on the intestinal microbiota in the Simulator of the Human Intestinal Microbial Ecosystem (SHIME) and in the rat. Environ. Sci. Pollut. Res. Int. 2013, 20, 2726–2734.
130. Freire, C.; Koifman, S. Pesticides, depression and suicide: A systematic review of the epidemiological evidence. Int. J. Hyg. Environ. Health 2013, 216, 445–460.
131. Rhee, S.Y.; Hwang, Y.C.; Woo, J.T.; Sinn, D.H.; Chin, S.O.; Chon, S.; Kim, Y.S. Blood lead is significantly associated with metabolic syndrome in Korean adults: An analysis based on the Korea National Health and Nutrition Examination Survey (KNHANES), 2008. Cardiovasc. Diabetol. 2013, 12, 9.
132. Peters, J.L.; Kubzansky, L.D.; Ikeda, A.; Fang, S.C.; Sparrow, D.; Weisskopf, M.G.; Wright, R.O.; Vokonas, P.; Hu, H.; Schwartz, J.; et al. Lead concentrations in relation to multiple biomarkers of cardiovascular disease: The Normative Aging Study. Environ. Health Perspect. 2012, 120, 361–366.
133. Braun, J.M.; Hoffman, E.; Schwartz, J.; Sanchez, B.; Schnaas, L.; Mercado-Garcia, A.; Solano-Gonzalez, M.; Bellinger, D.C.; Lanphear, B.P.; Hu, H.; et al. Assessing windows of susceptibility to lead-induced cognitive deficits in Mexican children. Neurotoxicology 2012, 33, 1040–1047.
134. Kish, L.; Hotte, N.; Kaplan, G.G.; Vincent, R.; Tso, R; Gänzle, M.; Rioux, K.P.; Thiesen, A.; Barkema, H.W.; Wine, E.; et al. Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome. PLoS One 2013, 8, e62220.
135. Jalaludin, B.; Cowie, C. Particulate air pollution and cardiovascular disease—It is time to take it seriously. Rev. Environ. Health 2014, 29, 129–132.
136. Matsui, E.C. Environmental exposures and asthma morbidity in children living in urban neighborhoods. Allergy 2014, 69, 553–558.
137. Choi, J.J.; Eum, S.Y.; Rampersaud, E.; Dauner, S.; Abreu, M.T.; Toborek, M. Exercise attenuates PCB-induced changes in the mouse gut microbiome. Environ. Health Perspect. 2013, 121, 725–730.
138. Heilmann, C.; Budtz-Jørgensen, E.; Nielsen, F.; Heinzow, B.; Weihe, P.; Grandjean, P. Serum concentrations of antibodies against vaccine toxoids in children exposed perinatally to immunotoxicants. Environ. Health Perspect. 2010, 118, 1434–1438.
139. Grandjean, P.; Poulsen, L.K.; Heilmann, C.; Steuerwald, U.; Weihe, P. Allergy and sensitization during childhood associated with prenatal and lactational exposure to marine pollutants. Environ. Health Perspect. 2010, 118, 1429–1433.
140. Lutgendorff, F.; Akkermans, L.M.; Söderholm, J.D. The role of microbiota and probiotics in stress-induced gastro-intestinal damage. Curr. Mol. Med. 2008, 8, 282–298.
141. Bailey, M.T.; Dowd, S.E.; Galley, J.D.; Hufnagle, A.R.; Allen, R.G.; Lyte, M. Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation. Brain Behav. Immun. 2011, 25, 397–407.
142. Galley, J.D.; Nelson, M.C.; Yu, Z.; Dowd, S.E.; Walter, J.; Kumar, P.S.; Lyte, M.; Bailey, M.T. Exposure to a social stressor disrupts the community structure of the colonic mucosa-associated microbiota. BMC Microbiol. 2014, 14, 189.
143. Cesario, A.; Auffray, C.; Agusti, A.; Apolone, G.; Balling. R.; Barbanti, P.; Bellia, A.; Boccia, S.; Bousquet, J.; Cardaci, V.; et al. A systems medicine clinical platform for understanding and managing non-communicable diseases. Curr. Pharm. Des. 2014, 20, 5945–5956.
144. Aw, W.; Fukuda, S. Toward the comprehensive understanding of the gut ecosystem via metabolomics-based integrated omics approach. Semin. Immunopathol. 2015, 37, 5–16.
145. Dinan, T.G.; Borre, Y.E.; Cryan, J.F. Genomics of schizophrenia: Time to consider the gut microbiome? Mol. Psychiatry 2014, 19, 1252–1257.
146. Mao, L.; Franke, J. Symbiosis, dysbiosis and rebiosis—The value of metaproteomics in human microbiome monitoring. Proteomics 2014, doi:10.1002/pmic.201400329.
147. Shenderov, B.A.; Midtvedt, T. Epigenomic programing: A future way to health? Microb. Ecol. Health. Dis. 2014, 25, doi:10.3402/mehd.v25.24145.2014.
148. Dietert, R.R.; DeWitt, J.C.; Germolec, D.R.; Zelikoff, J.T. Breaking patterns of environmentally influenced disease for health risk reduction: Immune perspectives. Environ. Health Perspect 2010, 118, 1091–1099.
149. De Maeseneer, J.; Boeckxstaens, P. Care for noncommunicable diseases (NCDs): Time for a paradigm-shift. World Hosp. Health Serv. 2011, 47, 30–33.
150. Ginsberg, G.L.; Dietert, R.R.; Sonawane, B.R. Susceptibility based upon chemical interaction with disease processes: Potential implications for risk assessment. Curr. Environ. Health Rep. 2014, 1, 314–324.
151. Tjellström, B.; Högberg, L.; Stenhammar, L.; Fälth-Magnusson, K.; Magnusson, K.E.; Norin, E.; Sundqvist, T.; Midtvedt, T. Faecal short-chain fatty acid pattern in childhood coeliac disease is normalised after more than one year’s gluten-free diet. Microb. Ecol. Health Dis. 2013, 25, 24.
152. Scott, K.P.; Antoine, J.M.; Midtvedt, T.; van Hemert, S. Manipulating the gut microbiota to maintain health and treat disease. Microb. Ecol. Health Dis. 2015, 26, 25877.
153. Obieglo, K.; van Wijck, Y.; de Kleijn, S.; Smits, H.H.; Taube, C. Microorganism-induced suppression of allergic airway disease: Novel therapies on the horizon? Expert. Rev. Respir. Med. 2014, 8, 717–530.
154. Chen, W.X.; Ren, L.H.; Shi, R.H. Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. World J. Gastroenterol. 2014, 20, 15657–15663.
155. Udayappan, S.D.; Hartstra, A.V.; Dallinga-Thie, G.M.; Nieuwdorp, M. Intestinal microbiota and faecal transplantation as treatment modality for insulin resistance and type 2 diabetes mellitus. Clin. Exp. Immunol. 2014, 177, 24–29.
156. Brahe, L.K.; Astrup, A.; Larsen, L.H. Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? Obes. Rev. 2013, 14l, 950–959.
157. Tilg, H.; Moschen, A.R. Microbiota and diabetes: An evolving relationship. Gut 2014, 63, 1513–1521.
158. MacFabe, D.F. Short-chain fatty acid fermentation products of the gut microbiome: Implications in autism spectrum disorders. Microb. Ecol. Health Dis. 2012, doi:10.3402/mehd.v23i0.19260.
159. Walker, A.W.; Sanderson, J.D.; Churcher, C.; Parkes, G.C.; Hudspith, B.N.; Rayment, N.; Brostoff, J.; Parkhill, J.; Dougan, G.; Petrovska, L. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011, 11, 7.
160. Zhang, Y.; Zheng, Y.; Hu, J.; Du, N.; Chen, F. Functional diversity of the microbial community in healthy subjects and periodontitis patients based on sole carbon source utilization. PLoS One 2014, 9, e91977.
161. Petersen, C.; Round, J.L. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014, 16, 1024–1033.
162. Allen-Vercoe, E. Bringing the gut microbiota into focus through microbial culture: Recent progress and future perspective. Curr. Opin. Microbiol. 2013, 16, 625–629.
163. Dietert, R.R.; Silbergeld, E.K. Biomarkers for the 21st century: Listening to the microbiome. Toxicol. Sci. 2015, in press.
164. Joice, R.; Yasuda, K.; Shafquat, A.; Morgan, X.C.; Huttenhower, C. Determining microbial products and identifying molecular targets in the human microbiome. Cell Metab. 2014, 20, 731–741.
165. Wu, G.D.; Compher, C.; Chen, E.Z.; Smith, S.A.; Shah, R.D.; Bittinger, K.; Chehoud, C.; Albenberg, L.G.; Nessel, L.; Gilroy, E.; et al. Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production. Gut 2014, doi:10.1136/gutjnl-2014-308209.
166. Di Bella, J.M.; Bao, Y.; Gloor, G.B.; Burton, J.P.; Reid. G. High throughput sequencing methods and analysis for microbiome research. J. Microbiol. Methods 2013, 95, 401–414.
167. Gosalbes, M.J.; Llop, S.; Vallès, Y.; Moya, A.; Ballester, F.; Francino, M.P. Meconium microbiota types dominated by lactic acid or enteric bacteria are differentially associated with maternal eczema and respiratory problems in infants. Clin. Exp. Allergy 2013, 43, 198–211.
168. Hu, J.; Nomura, Y.; Bashir, A.; Fernandez-Hernandez, H.; Itzkowitz, S.; Pei, Z.; Stone, J.; Loudon, H.; Peter, I. Diversified microbiota of meconium is affected by maternal diabetes status. PLoS One 2013, 8, e78257.
169. De Vrese, M.; Schrezenmeir, J. Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 2008, 111, 1–66.
170. Gibson, G.R. Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. J. Nutr. 1999, 129, 1438S–1441S.
171. Lohner, S.; Küllenberg, D.; Antes, G.; Decsi, T.; Meerpohl, J.J. Prebiotics in healthy infants and children for prevention of acute infectious diseases: A systematic review and meta-analysis. Nutr. Rev. 2014, 72, 523–531.
172. Francino, M.P. Early development of the gut microbiota and immune health. Pathogens 2014, 3, 769–790.
173. Akatsu, H.; Nagafuchi, S.; Kurihara, R.; Okuda, K.; Kanesaka, T.; Ogawa, N.; Kanematsu, T. Takasugi, S.; Yamaji, T.; Takami, M.; et al. Enhanced vaccination effect against influenza by prebiotics in elderly patients receiving enteral nutrition. Geriatr. Gerontol. Int. 2015, doi:10.1111/ggi.12454.
174. Ladirat, S.E.; Schoterman, M.H.; Rahaou, I.H.; Mars, M.; Schuren, F.H.; Gruppen, H.; Nauta, A.; Schols, H.A. Exploring the effects of galacto-oligosaccharides on the gut microbiota of healthy adults receiving amoxicillin treatment. Br. J. Nutr. 2014, 112, 536–546.
175. West, C.E.; Renz, H.; Jenmalm, M.C.; Kozyrskyj, A.L.; Allen, K.J.; Vuillermin, P.; Prescott, S.L.; In-FLAME Microbiome Interest Group. The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies. J. Allergy Clin. Immunol. 2015, 135, 3–13.
176. Beserra, B.T.; Fernandes, R.; do Rosario, V.A.; Mocellin, M.C.; Kuntz, M.G.; Trindade, E.B. A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity. Clin. Nutr. 2014, doi:10.1016/j.clnu.2014.10.004.
177. Mirmiran, P.; Bahadoran, Z.; Azizi, F. Functional foods-based diet as a novel dietary approach for management of type 2 diabetes and its complications: A review. World J. Diabetes 2014, 5, 267–281.
178. Deshpande, G.; Rao, S.; Patole, S.; Bulsara, M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010, 125, 921–930.
179. Zhang, J.; Wang, L.; Guo, Z.; Sun, Z.; Gesudu, Q.; Kwok, L.; Zhang, M.; Zhang, H. 454 pyrosequencing reveals changes in the faecal microbiota of adults consuming Lactobacillus casei Zhang. FEMS Microbiol. Ecol. 2014, 88, 612–622.
180. Forsberg, A.; Abrahamsson, T.R.; Björkstén, B.; Jenmalm, M.C. Pre-and post-natal Lactobacillus reuteri supplementation decreases allergen responsiveness in infancy. Clin. Exp. Allergy 2013, 43, 434–442.
181. Wang, I.J.; Wang, J.Y. Children with atopic dermatitis show clinical improvement after Lactobacillus exposure. Clin. Exp. Allergy 2015, doi:10.1111/cea.12489.
182. Kim, S.O.; Ah, Y.M.; Yu, Y.M.; Choi, K.H.; Shin, W.G.; Lee, J.Y. Effects of probiotics for the treatment of atopic dermatitis: A meta-analysis of randomized controlled trials. Ann. Allergy Asthma Immunol. 2014, 113, 217–226.
183. Matsumoto, M.; Ebata, T.; Hirooka, J.; Hosoya, R.; Inoue, N.; Itami, S.; Tsuji, K.; Yaginuma, T.; Muramatsu, K.; Nakamura, A.; et al. Antipruritic effects of the probiotic strain LKM512 in adults with atopic dermatitis. Ann. Allergy Asthma Immunol. 2014, 113, 209–216.
184. Groeger, D.; O’Mahoney, L.; Murphy, E.F.; Bourke, J.F.; Dinan, T.G.; Kiely, B.; Shanahan, F.; Quigley, E.M.M. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes 2013, 4, 325–339.
185. Luoto, R.; Ruuskanen, O.; Waris, M.; Kalliomäki, M.; Salminen, S.; Isolauri, E. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: A randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2014, 133, 405–413.
186. Shen, J.; Zuo, Z.X.; Mao, A.P. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: Meta-analysis of randomized controlled trials. Inflamm. Bowel. Dis. 2014, 20, 21–35.
187. Kovachev, S.M.; Vatcheva-Dobrevska, R.S. Local probiotic therapy for vaginal Candida albicans infections. Probiotics Antimicrob. Proteins 2014, doi:10.1007/s12602-014-9176-0.
188. Famouri, F.; Khoshdel, A.; Golshani, A.; Kheiri, S.; Saneian, H.; Kelishadi, R. Effects of synbiotics on treatment of children with failure to thrive: A triple blind placebo-controlled trial. J. Res. Med. Sci. 2014, 19, 1046–1050.
189. Rammohan, A.; Sathyanesan, J.; Rajendran, K.; Pitchaimuthu, A.; Perumal, S.K.; Balaraman, K.; Ramasamy, R.; Palaniappan, R.; Govindan, M. Synbiotics in surgery for chronic pancreatitis: Are they truly effective? A single blind prospective randomized control trial. Ann. Surg. 2015, doi:10.1097/SLA.0000000000001077.
190. Rajkumar, H.; Kumar, M.; Das, N.; Kumar, S.N.; Challa, H.R.; Nagpal, R. Effect of probiotic Lactobacillus salivarius UBL S22 and prebiotic fructo-oligosaccharide on serum lipids, inflammatory markers, insulin sensitivity, and gut bacteria in healthy young volunteers: A randomized controlled single-blind pilot study. J. Cardiovasc. Pharmacol. Ther. 2014, doi:10.1177/1074248414555004.
191. Nascimento, M.; Aguilar-Nascimento, J.E.; Caporossi, C.; Castro-Barcellos, H.M.; Motta, R.T. Efficacy of synbiotics to reduce acute radiation proctitis symptoms and improve quality of life: A randomized, double-blind, placebo-controlled pilot trial. Int. J. Radiat. Oncol. Biol. Phys. 2014, 90, 289–295.
192. Rogha, M.; Esfahani, M.Z.; Zargarzadeh, A.H. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: A randomized placebo-controlled trial. Gastroenterol Hepatol. Bed. Bench 2014, 7, 156–163.
193. Rossi, M.; Johnson, D.W.; Morrison, M.; Pascoe, E.; Coombes, J.S.; Forbes, J.M.; McWhinney, B.C.; Ungerer, J.P.; Dimeski, G.; Campbell, K.L. SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): A protocol of placebo-controlled randomised cross-over trial. BMC Nephrol. 2014, 15, 106.
194. Eslamparast, T.; Poustchi, H.; Zamani, F.; Sharafkhah, M.; Malekzadeh, R.; Hekmatdoost, A. Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study. Am. J. Clin. Nutr. 2014, 99, 535–542.
195. Borody, T.J.; Brandt, L.J.; Paramsothy, S. Therapeutic faecal microbiota transplantation: Current status and future developments. Curr. Opin. Gastroenterol 2014, 30, 97–105.
196. Kelly, C.R.; de Leon, L.; Jasutkar, N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: Methodology and results. J. Clin. Gastroenterol 2012, 46, 145–149.
197. Kronman, M.P.; Nielson, H.J.; Adler, A.L.; Giefer, M.J.; Wahbeh, G.; Singh, N.; Zerr, D.M.; Suskind, D.L. Fecal microbiota transplantation via nasogastric tube for recurrent C. difficile infection in pediatric patients. J. Pediatr. Gastroenterol Nutr. 2015, 60, 23–26.
198. Rubin, T.A.; Gessert, C.E.; Aas, J.; Bakken, J.S. Fecal microbiome transplantation for recurrent Clostridium difficile infection: Report on a case series. Anaerobe 2013, 19, 22–26.
199. Colman, R.J.; Rubin, D.T. Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. J. Crohns Colitis 2014, 8, 1569–1581.
200. Xu, M.Q.; Cao, H.L.; Wang, W.Q.; Wang, S.; Cao, X.C.; Yan, F.; Wang, B.M. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J. Gastroenterol 2015, 21, 102–111.
201. Sha, S.; Liang, J.; Chen, M.; Xu, B.; Liang, C.; Wei, N.; Wu, K. Systematic review: Faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment. Pharmacol. Ther. 2014, 39, 1003–1032.
202. Kunde, S.; Pham, A.; Bonczyk, S.; Crumb, T.; Duba, M.; Conrad, H., Jr.; Cloney, D.; Kugathasan, S. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 2013, 56, 597–601.
203. Lo Vecchio, A.; Cohen, M.B. Fecal microbiota transplantation for Clostridium difficile infection: Benefits and barriers. Curr. Opin. Gastroenterol. 2014, 30, 47–53.
204. Brandt, L.J. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am. J. Gastroenterol. 2013, 108, 177–185.